Efforts to improve health care in Africa take on many forms, the Novartis Institutes for BioMedical Research (NIBR) is contributing by discovering novel medicines that address patient needs.
Cells have mechanical components. Learn how GNF studies cell membranes to figure out what makes them tick.
Up the stairs to the entrance of the plane they climb: small children with cloudy eyes, teens with thick glasses and practiced squints, adults with dark shades.
When Parisa Zamiri was a young girl in Iran, it made her sad to see how her blind grandmother struggled with day-to-day tasks. “I grew up with her touching the stove to see if it was on. And so, she always had burns on her hands,” Zamiri recalls.
Two years ago, the global community convened in London to hold a significant international meeting on neglected tropical diseases (NTDs). These commitments are now known as the London Declaration. On April 2, this group of partners came together once more to discuss progress toward the goals outlined in 2012.
Novartis is working to tackle the problem of counterfeit drugs, which are a threat to patient health.
Patients with glaucoma, which affects 60 million people worldwide, can lose up to 40 percent of their sight before they begin to notice any change in vision.
Genetics often underlies mental health. Learn how NIBR researchers are trying to identify associated drug targets to improve the conditions.
The Novartis Institute for BioMedical Research helps its researchers stay fresh and creative. Read about our mini-sabbatical program.
Novartis has helped fight the disease by donating multidrug therapy (MDT) to leprosy patients worldwide through the World Health Organization.
Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.
This site is intended for a global audience.